Payment overview · 2025
General Payments
$298.16
20 reported records · 7 companies
Healthcare provider profile · identity verified
Gretchen H Bowling, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · JOHNSON CITY, TN · NPI 1831382449
Verified facts
What the public records show
CMS Open Payments records show Gretchen H Bowling, M.D. received $298.16 in general payments during 2025 across 20 reported records.
ABBVIE INC. accounted for 48.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $145.40 | 48.8% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.78 | 23.7% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.68 | 6.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.72 | 5.9% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $16.83 | 5.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.40 | 4.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.35 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $298.16 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.78 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $50.69 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.69 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $50.66 | 4 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $44.05 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 105 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
102 | 23 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
105 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 323 | 89 |
| Omeprazole | Omeprazole | 317 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 313 | 81 |
| Atorvastatin Calcium | Atorvastatin Calcium | 309 | 80 |
| Losartan Potassium | Losartan Potassium | 291 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 227 | 66 |
| Gabapentin | Gabapentin | 202 | 41 |
| Lisinopril | Lisinopril | 187 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 179 | 54 |
| Potassium Chloride | Potassium Chloride | 168 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 157 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 152 | 28 |
| Alprazolam | Alprazolam | 145 | 22 |
| Clonazepam | Clonazepam | 141 | 17 |
| Metformin Hcl Er | Metformin Hcl | 138 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 40 |
| Trazodone Hcl | Trazodone Hcl | 133 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 125 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 124 | 33 |
| Simvastatin | Simvastatin | 123 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 30 |
| Furosemide | Furosemide | 115 | 34 |
| Meloxicam | Meloxicam | 115 | 39 |
| Tramadol Hcl | Tramadol Hcl | 115 | 20 |
| Buspirone Hcl | Buspirone Hcl | 110 | 29 |
| Ozempic | Semaglutide | 105 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 39 |
| Metformin Hcl | Metformin Hcl | 103 | 27 |
| Synthroid | Levothyroxine Sodium | 102 | 23 |
| Pregabalin | Pregabalin | 100 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 98 | 28 |
| Sertraline Hcl | Sertraline Hcl | 84 | 22 |
| Spironolactone | Spironolactone | 84 | 26 |
| Bupropion Xl | Bupropion Hcl | 80 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 23 |
| Eliquis | Apixaban | 75 | 15 |
| Celecoxib | Celecoxib | 74 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 39 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 74 | 17 |
| Famotidine | Famotidine | 73 | 27 |
| Montelukast Sodium | Montelukast Sodium | 71 | 17 |
| Lorazepam | Lorazepam | 67 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 16 |
| Alendronate Sodium | Alendronate Sodium | 59 | 16 |
| Lovastatin | Lovastatin | 57 | 14 |
| Carvedilol | Carvedilol | 56 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 16 |
| Glimepiride | Glimepiride | 55 | 13 |
| Allopurinol | Allopurinol | 52 | 17 |
| Fluconazole | Fluconazole | 50 | 26 |
| Atenolol | Atenolol | 49 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 49 | 19 |
| Jardiance | Empagliflozin | 49 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 13 |
| Prednisone | Prednisone | 46 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | 11 |
| Benazepril Hcl | Benazepril Hcl | 44 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 15 |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | 11 |
| Sucralfate | Sucralfate | 41 | suppressed |
| Ibuprofen | Ibuprofen | 40 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Methocarbamol | Methocarbamol | 38 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 36 |
| Glipizide Er | Glipizide | 37 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 35 | suppressed |
| Telmisartan | Telmisartan | 35 | suppressed |
| Carbamazepine | Carbamazepine | 34 | suppressed |
| Cefdinir | Cefdinir | 34 | 29 |
| Estradiol | Estradiol | 34 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 17 |
| Cephalexin | Cephalexin | 32 | 11 |
| Ramipril | Ramipril | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 18 |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 14 |
| Irbesartan | Irbesartan | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Colchicine | Colchicine | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $298.16 · 20 records | ABBVIE INC. | CAMZYOS, Cologuard Collection Kit, Dexcom G6 Transmitter, Ozempic, QULIPTA, TONMYA, TRELEGY ELLIPTA, UBRELVY, VIBERZI, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error